Page 72 - PRECONGRESS COURSE 03

ACTIVATION DEFICIENCIES
WHERE THE FUTURE LIES?
• Efficacy
• To be demonstrated further
• Increased number of patients • Using standardized protocol
• Safety
• Still an experimental approach
• Notes of caution with respect to effectiveness and non-physiological responses
• When to use AOA?
• Need for careful patient selection for well-defined indications
• Improving on assessment strategies that are clinically applicable and predictive • PLC zeta as a prognostic and diagnostic marker
• On the horizon...
• rPLC zeta as the activating agent (Kashir et al., 2011; Yoon et al., 2012; Nomikos et al., 2013)
• Other molecular players or targets (e.g. PAWP, yet undiscovered oocyte targets)
RECOMMENDATIONS
• Expand on basic understanding of fertilization and the study of failure cases (all types) → new candidates for improved diagnostic, prognostic, and therapeutic options
• Identify mutations and study their functional impacts
• Evaluate the involvement of environmental, lifestyle, and other
factors
• Consider potential limitations of intervention approaches: only a band-aid approach?
• Translate findings towards improving patient management and the pursuit of ‘physiological’ intervention approaches
72
Page 68 of 102